Literature DB >> 25552362

Sputum volume predicts sputum mycobacterial load during the first 2 weeks of antituberculosis treatment.

Miriam N Karinja1, Tonya M Esterhuizen2, Sven O Friedrich3, Andreas H Diacon4.   

Abstract

Disease severity in patients with pulmonary tuberculosis is associated with mycobacterial sputum load. To ascertain whether reduced sputum production during treatment is a useful clinical sign of improvement, we analyzed the mycobacterial loads of 5,552 sputum samples collected from 439 newly diagnosed sputum smear-positive tuberculosis patients who participated in six 14-day studies of antituberculosis treatment. Sputum volumes were categorized as low (<6 ml), medium (6 to 10 ml), or large (>10 ml), and mycobacterial load was measured by the time to positivity in liquid culture and the CFU counts on solid culture. The association of sputum volume with mycobacterial load was estimated with multiple linear regression models adjusted for repeated measures. The predictor variables were sputum volume category, treatment day, specific study , and the interaction of sputum volume category and treatment day. Mycobacterial load was significantly associated only with the day on treatment and sputum volume, which tended to decrease with ongoing treatment. With the volume held constant, each day on treatment decreased the log CFU by 0.082 (P<0.001) and increased the time to positivity (TTP) by 1.04 h (P<0.001). From low to medium and from medium to large sputum volumes, the log CFU/ml increased by 0.265 (P<0.003) and 0.490 (P<0.001), respectively, and the TTP decreased by 1.17 h (P<0.001) and 1.30 h (P<0.001), respectively, for a given day of treatment. The variability of the sputum load measurements increased with the day of treatment and lower sputum volumes. The significant association of sputum volume and mycobacterial load validates decreasing sputum production as a clinical sign of improvement during early antituberculosis treatment.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552362      PMCID: PMC4365216          DOI: 10.1128/JCM.02379-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Authors:  Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.

Authors:  R Hafner; J A Cohn; D J Wright; N E Dunlap; M J Egorin; M E Enama; K Muth; C A Peloquin; N Mor; L B Heifets
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

3.  PARA-AMINOSALICYLIC acid treatment in pulmonary tuberculosis.

Authors: 
Journal:  Am Rev Tuberc       Date:  1950-05

4.  Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.

Authors:  C M Bark; P Gitta; S Ogwang; M Nsereko; B A Thiel; W H Boom; K D Eisenach; M L Joloba; J L Johnson
Journal:  Int J Tuberc Lung Dis       Date:  2013-11       Impact factor: 2.373

5.  Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents.

Authors:  A H Diacon; J S Maritz; A Venter; P D van Helden; R Dawson; P R Donald
Journal:  Clin Microbiol Infect       Date:  2011-08-18       Impact factor: 8.067

6.  Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis.

Authors:  M D Epstein; N W Schluger; A L Davidow; S Bonk; W N Rom; B Hanna
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

7.  Phase II dose-ranging trial of the early bactericidal activity of PA-824.

Authors:  Andreas H Diacon; Rodney Dawson; Jeannine du Bois; Kim Narunsky; Amour Venter; Peter R Donald; Christo van Niekerk; Ngozi Erondu; Ann M Ginsberg; Piet Becker; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

8.  Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

Authors:  A C Hesseling; G Walzl; D A Enarson; N M Carroll; K Duncan; P T Lukey; C Lombard; P R Donald; K A Lawrence; R P Gie; P D van Helden; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2010-05       Impact factor: 2.373

Review 9.  Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.

Authors:  Michael L Wilson
Journal:  Arch Pathol Lab Med       Date:  2013-06       Impact factor: 5.534

10.  High prevalence of tuberculosis and insufficient case detection in two communities in the Western Cape, South Africa.

Authors:  Mareli Claassens; Cari van Schalkwyk; Leonie den Haan; Sian Floyd; Rory Dunbar; Paul van Helden; Peter Godfrey-Faussett; Helen Ayles; Martien Borgdorff; Donald Enarson; Nulda Beyers
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

View more
  6 in total

1.  Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Authors:  Andreas H Diacon; Elana van Brakel; Nacer Lounis; Paul Meyvisch; Ben Van Baelen; Tine De Marez; Eilidh Jenkins; Brian Dannemann
Journal:  Am J Respir Crit Care Med       Date:  2017-12-15       Impact factor: 21.405

2.  Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring.

Authors:  Ines Labugger; Jan Heyckendorf; Stefan Dees; Emilia Häussinger; Christian Herzmann; Thomas A Kohl; Elvira Richter; Eric Rivera-Milla; Christoph Lange
Journal:  Infection       Date:  2016-10-31       Impact factor: 3.553

3.  Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.

Authors:  Robin J Svensson; Wilber Sabiiti; Gibson S Kibiki; Nyanda E Ntinginya; Nilesh Bhatt; Geraint Davies; Stephen H Gillespie; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden.

Authors:  Emmanuel Musisi; Christian Dide-Agossou; Reem Al Mubarak; Karen Rossmassler; Abdul Wahab Ssesolo; Sylvia Kaswabuli; Patrick Byanyima; Ingvar Sanyu; Josephine Zawedde; William Worodria; Martin I Voskuil; Rada M Savic; Payam Nahid; J Lucian Davis; Laurence Huang; Camille M Moore; Nicholas D Walter
Journal:  Microbiol Spectr       Date:  2021-09-08

5.  Exploration of Synergistic Action of Cell Wall-Degrading Enzymes against Mycobacterium tuberculosis.

Authors:  Loes van Schie; Katlyn Borgers; Gitte Michielsen; Evelyn Plets; Marnik Vuylsteke; Petra Tiels; Nele Festjens; Nico Callewaert
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

6.  Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis.

Authors:  R J Svensson; Ush Simonsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.